Multiple sclerosis: Recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment

Current Opinion in Neurology

Volumn 14, Issue 3, 2001, Pages 259-269

  Lucchinetti, Claudia ^a   Brück, Wolfgang ^b   Noseworthy, John ^a  

^a MAYO CLINIC   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; LIGAND;

CLINICAL TRIAL; DEMYELINATING DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

AXONS; BRAIN; CLADRIBINE; HUMANS; IMMUNIZATION, PASSIVE; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PEPTIDES;

EID: 0034981293     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200106000-00002     Document Type: Review

References (120)

1. Immunology of multiple sclerosis
2. The genetic of multiple sclerosis. A review
3. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome
4. The adhesion molecule and cytokine profile of MS lesions
5. Cytokines and the pathogenesis of multiple sclerosis
6. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions
7. Expression of specific chemokines and chemokine receptors in the central nervous system of muitiple sclerosis patients
8. Increased numbers of CCR5+ interferon-gamma and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients
9. Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions
10. Aberrant T cell migration toward RANTES and MIP-1alpha in patients with multiple sclerosis: Overexpression of chemokine receptor CCR5
11. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
12. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis
13. Clonal expansion of CD8 T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction
14. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
15. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
16. Identification of autoantibodies associated with myelin damage in multiple sclerosis
17. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions
18. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients
19. Restricted use of VH4 germline segments in acute MS brain
20. Clonal expansion and somatic hypermutation of Vh genes of B cells from cerebrospinal fluid in multiple sclerosis
21. Comparison of lgG heavy chain sequences in MS and SSPE brain reveals an antigen-driven response
22. Myelin basic protein specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease
23. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate
24. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
25. Pulsed monoclonal antibody treatment and autoimmune thryoid disease in multiple sclerosis
26. The histology of disseminated sclerosis
27. The significance of perivascular infiltrations in multiple sclerosis
28. Ultrastructure of multiple sclerosis
29. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role for inflammation?
30. The lesion in multiple sclerosis: Clinical, pathological, and magnetic resonance imaging considerations
31. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of primary demyelinating lesion
32. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis
33. Double-blind placebo-controlled MR monitored exploratory trial of chimeric anti-CD4 antibodies in NS
34. Axonal transsection in the lesions of multiple sclerosis
35. Axonal damage in acute multiple sclerosis
36. Axonal pathology in multiple sclerosis: A historical note
37. The longstanding MS lesion. A quantitative MRI and electron microscopic study
38. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
39. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
40. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology
41. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with clinical subgroup?
42. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
43. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive and remyelinated lesions
44. Axonal changes in chronic demyelinated cervical spinal cord plaques
45. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system
46. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor
47. Nitric oxide is an autocrine regulator of Na+ currents in axotomized C-type DRG neurons
48. Temporary conduction block and axonal loss in inflammatory neurologic disease
49. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology
50. Glutamate excitotoxicity in a model of multiple sclerosis
51. Multiple sclerosis: Lessons learned from neuropathology
52. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis
53. Herpes simplex virus in postmortem multiple sclerosis brain tissue
54. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
55. The HHV6 paradox: Ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach
56. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis
57. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis
58. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis
59. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS
60. Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients
61. Lack of Chlamydia infection of the central nervous system in multiple sclerosis
62. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases
63. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis
64. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis
65. Oligodendrocyte precursor cells in chronic multiple sclerosis lesions
66. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions
67. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging
68. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
69. Magnetic resonance (MR) imaging as a marker for multiple sclerosis
70. Correlation between MR and clinical findings of disease activity in multiple sclerosis
71. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis
72. Open-ring imaging sign. Highly specific for atypical brain demyelination
73. High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions
74. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging volume
75. Serial magnetic resonance imaging in multiple sclerosis: Correlation with attacks, disability, and disease stage
76. Magnetization-transfer histogram analysis of the cervical cord in patients with multiple sclerosis
77. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: A study with magnetisation transfer ratio histogram analysis
78. Serial analysis of magnetization-transfer histograms and expanded disability status scale scores in patients with relapsing - Remitting multiple sclerosis
79. Magnetization transfer ratio of the spinal cord in multiple sclerosis: Relationship to atrophy and neurologic disability
80. Correlations between clinical and MRI involvement in multiple sclerosis: Assessment using T1, T2 and MT histograms
81. Whole-brain diffusion MR histograms differ between MS subtypes
82. Demyelinating plaques in relapsing - Remitting and secondary-progressive multiple sclerosis: Assessment with diffusion MR imaging
83. Axonal pathology in multiple sclerosis: Relationship to neurologic disability
84. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis
85. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
86. Lesion heterogeneity in multiple sclerosis: A study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations
87. Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter diseases
88. Correlating magnetic resonance imaging markers of axonal injury and demyelination in motor impairment secondary to stroke and multiple sclerosis
89. Total brain N-acetylaspartate. A new measure of disease load in MS
90. Relating axonal injury to functional recovery in MS
91. Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis
92. Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions
93. Brain atrophy as a surrogate marker in MS. Faster, simpler, better?
94. Progressive cerebral atrophy in MS. A serial study using registered, volumetric MRI
95. Quantitative brain volumetric analysis from patients with multiple sclerosis: A follow-up study
96. Brain atrophy in relapsing - Remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
97. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
98. Brain atrophy in relapsing - Remitting multiple sclerosis: Relationship with 'black holes', disease duration and clinical disability
99. Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis
100. Memory dysfunction in multiple sclerosis corresponds to juxtacortical lesion load on fast fluid-attenuated inversion-recovery MR images
101. Cortical deficits in multiple sclerosis on the basis of subcortical lesions
102. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS
103. A multiparametric MRI study of frontal lobe dementia in multiple sclerosis
104. MR lesion load and cognitive function in patients with relapsing - Remitting multiple sclerosis
105. Changes in normal appearing brain tissue and cognitive impairment in multiple sclerosis
106. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis
107. A magnetization transfer histogram study of normal-appearing brain tissue in MS
108. A wallerian degeneration pattern in patients at risk for MS
109. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis. A serial diffusion MRI study
110. Intramuscular interferon beta·1a therapy initiated during a first demyelinating event in multiple sclerosis
111. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
112. Glatiramer acetate (Copaxone) treatment in relapsing - Remitting MS: Quantitative MR assessment
113. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing - Remitting multiple sclerosis: A multi-center randomized, double-blind, placebo-controlled study extended by open-label treatment
114. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
115. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
116. IV immunoglobulin does not reverse established weakness in MS - A double-blind, placebo-controlled trial
117. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
118. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
119. A phase I trial of solubilized DR2: MBp(84-102) (AG284) in multiple sclerosis